Booms, Busts, and Recoveries Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Booms, Busts, and Recoveries

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: energyplay	2/4/2005 8:54:29 PM
	Read Replies (1) of 74559

FDA vs. COX -2 From David Miller on Minyanville.com - "The FDA briefing papers for the Advisory Panel meeting on the COX-2 inhibitors are particularly bleak. It is apparent the FDA is considering banning the entire class or at least dramatically restricting their label. ...." This will hit Pfizer which has Celebrex and Bextra... I have puts on US Merck (NYSE:MRK) because the tort lawyers might hit the company like piranas over Vioxx. Pfizer is considerably cleaner with what did they know and when and what did they do than Merck is (or at least it appears that way today)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next